Navigation Links
GeoVax Update Provided at the BIO CEO & Investor Conference 2009
Date:2/11/2009

ATLANTA, Feb. 11 /PRNewswire-FirstCall/ -- GeoVax Labs, Inc. (OTC Bulletin Board: GOVX), an Atlanta-based, publicly traded biopharmaceutical company developing human vaccines for diseases caused by HIV-1 (Human Immunodeficiency Virus) and other infectious agents, today announced that Robert McNally, Ph.D., Chief Executive Officer and President, presented a corporate update at the Eleventh Annual BIO CEO & Investor Conference 2009, held at the Waldorf-Astoria Hotel, in New York.

Dr. McNally presented a corporate overview of GeoVax and its DNA/MVA vaccine technology, showcasing the scientific rationale and encouraging data from the Company's completed studies and trials. Among the points discussed by Dr. McNally were:

  • World class science and collaboration with leading institutions. Dr. McNally informed the audience of unique scientific collaboration between Emory University, the National Institutes of Health (NIH) and the Centers for Disease Control and Prevention (CDC), which led to the formation of GeoVax and the exclusive license of technology developed at these institutions.
  • Large market opportunity. Dr. McNally presented information on the very attractive market opportunity available for a successful HIV/AIDS vaccine. GeoVax's unique vaccine with its potential use in both preventative and therapeutic applications holds promise for not only addressing an unmet medical need, but also for commercial success.
  • Intellectual property. Dr. McNally briefly reviewed GeoVax's patent portfolio, consisting of over 20 issued and pending patents covering the Company's vaccine technology and manufacturing methods.
  • Status of Phase 2a preventative clinical trial. Dr. McNally discussed the current status of the Company's Phase 2a preventative human vaccine trial. He noted that clinical sites had been activated and prospecti
    '/>"/>

SOURCE GeoVax Labs, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. GeoVax Labs, Inc. Second Quarter Financial Results and Operational Update
2. U.S. Government Awards $15 Million Grant to GeoVax Labs HIV/AIDS Vaccine Program
3. GeoVax Further Strengthens Management Team
4. GeoVax Labs, Inc. Announces Six Month Financial Results and Provides Operational Update
5. GeoVax Labs, Inc. Information To Be Available Through Standard & Poors Market Access Program
6. GeoVax Presents Data at AIDS Vaccine 2008 Conference
7. GeoVaxs DNA and MVA Vaccines Shipped to HIV Vaccine Trials Network for Use in the Upcoming Phase 2a Trial
8. GeoVax Labs, Inc. Announces Third Quarter 2008 Financial Results and Provides Operational Update
9. GeoVax to Present at the BIO CEO & Investor Conference 2009
10. GeoVax to Webcast Its Presentation at the BIO CEO & Investor 2009 Conference
11. CardioDynamics Provides 2007 Shareholder Meeting Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... GUELPH, ON , Oct. 20, 2014 /PRNewswire/ - BIOREM Inc. ... totalling $1.7 million which brings Q3 orders to $5.8 million and ... odour control projects in North America and ... "We continue to bid new projects at record levels," said ... values were higher at the end of Q3 than they have ...
(Date:10/20/2014)... 20, 2014 OncLive® ... Cancer Center at Thomas Jefferson University has joined ... the Strategic Alliance Partnership program, the Sidney Kimmel ... to raise awareness of the Center’s cutting-edge research ... projects. Clinicians and other health care professionals from ...
(Date:10/19/2014)... (PRWEB) October 20, 2014 ... Industry Meeting (ABIM). ABIM will take ... More information about ABIM 2014 is now ... , Delegates representing companies and organizations from ... and obtain information on the latest products ...
(Date:10/19/2014)... (PRWEB) October 19, 2014 The Asia-Pacific ... Analytics market in Asia-Pacific with analysis and forecast of ... million in 2014 to $208 million by 2019, at ... 2014 to 2019. , Browse through the TOC of ... idea of the in-depth analysis provided. It also provides ...
Breaking Biology Technology:Sidney Kimmel Cancer Center at Thomas Jefferson University Partners With OncLive 2Sidney Kimmel Cancer Center at Thomas Jefferson University Partners With OncLive 3The Asia-Pacific Speech Analytics market is estimated to reach $208 million by 2019 - New Report by MicroMarket Monitor 2The Asia-Pacific Speech Analytics market is estimated to reach $208 million by 2019 - New Report by MicroMarket Monitor 3The Asia-Pacific Speech Analytics market is estimated to reach $208 million by 2019 - New Report by MicroMarket Monitor 4
... have devised a way to squeeze light into tighter ... new technology in the fields of optical communications, miniature ... in passing light through gaps 200 nanometers wide, about ... hair. A group of UC Berkeley researchers led by ...
... 30 Nektar,Therapeutics (Nasdaq: NKTR ) will announce ... 2008 on Wednesday, August 6, 2008, after the,close of ... will host a conference call to review the results,beginning ... (PT)., The press release and a live audio-only ...
... SAN DIEGO, July 30 Neurocrine Biosciences,Inc. (Nasdaq: NBIX ... 30, 2008. For the second quarter of 2008, the Company ... compared with a net loss of,$26.4 million, or $(0.69) per ... the Company reported a net loss of $42.0 million, or ...
Cached Biology Technology:New technique to compress light could open doors for optical communications 2New technique to compress light could open doors for optical communications 3Nektar to Announce Financial Results for the Second Quarter of 2008 on Wednesday, August 6, 2008, After Close of U.S.-Based Financial Markets 2Neurocrine Biosciences Reports Second Quarter 2008 Results 2Neurocrine Biosciences Reports Second Quarter 2008 Results 3Neurocrine Biosciences Reports Second Quarter 2008 Results 4Neurocrine Biosciences Reports Second Quarter 2008 Results 5Neurocrine Biosciences Reports Second Quarter 2008 Results 6Neurocrine Biosciences Reports Second Quarter 2008 Results 7Neurocrine Biosciences Reports Second Quarter 2008 Results 8Neurocrine Biosciences Reports Second Quarter 2008 Results 9
(Date:10/16/2014)... thinking on how the bowel lining develops and, in ... cancer starts. , The researchers produced evidence that stem ... that are a feature of the bowel lining, and ... development, a controversial finding as scientists are still divided ... technologies, Dr Chin Wee Tan and Professor Tony Burgess ...
(Date:10/16/2014)... Virus causes severe respiratory tract infections and worldwide ... Scientists at VIB and Ghent University have succeeded ... this common virus infection. , Xavier Saelens ... paves the way for the development of a ... that causes suffering in numerous small children and ...
(Date:10/16/2014)... 2014 NXT-ID, Inc. (NASDAQ: NXTD ... authentication company focused on the growing mobile commerce market ... Wocket™, the Smart Wallet, at the 13 th ... leading global conference on the intersection of technology and ... Anderson , founder and publisher of the Strategic News ...
Breaking Biology News(10 mins):Cryptic clues drive new theory of bowel cancer development 2New perspectives for development of an RSV vaccine 2NXT-ID Inc. to Present at 13th Annual FiRe Conference 2NXT-ID Inc. to Present at 13th Annual FiRe Conference 3
... technical developments, and we will be increasingly moulded and changed ... future if we know what awaits us. So how can ... Applications Trends can provide sound assistance. It contains ... clear descriptions of all the main fields of technology. ...
... Sobrado, assistant professor of biochemistry ( http://www.biochem.vt.edu/faculty.php?lname=Sobrado&view=yes ) ... Tech, has received a Ralph E. Powe Junior ... that are essential for infection in two important ... presents the Powe award to faculty members who ...
... years ago: animals don,t pick their mates by pure chance ... factors. After decades of examining his work, experts agree that ... big question is, "What have we learned since then?" asks ... Adam Jones, an evolutional biologist who has studied Darwin,s work ...
Cached Biology News:Technology guide: Principles -- applications -- trends 2Powe Award supports research on how enzymes enable the pathogenicity of 2 human disease organisms 2Why do we choose our mates? Ask Charles Darwin, prof says 2
Trop-2 Purified Anti-Human clone 162-46, Isotype Mouse IgG 1 , 100 µg Consult technical datasheet for details....
... cloning of BAC (100+kb), fosmid (40kb), and ... stability than any othe BAC vector. On ... yields and easy recombinant DNA purification. Available ... (pSMART VC) vectors for the highest insert ...
... Error-free cloning of BAC (100+kb), fosmid (40kb), ... insert stability than any othe BAC vector. ... high yields and easy recombinant DNA purification. ... transcription-free (pSMART VC) vectors for the highest ...
Mouse Exodus 2 - 12kDa...
Biology Products: